CClinicalTrials.gg
Active, not recruitingNCT06436690Updated Jul 13, 2026

Optimizing Antibiotics Prescription

An interventional study of Diagnosis Mandate and Individualized Feedback in Antimicrobial Resistance, sponsored by Penn State University. Active, not recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Penn State University · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Interventions that are low-cost, do not add substantially to the physician workload, are consistent with good physician practices and WHO guidelines, and serve as a reminder on the risks of overprescribing antibiotics are critically needed. The overall goal of the proposed project is to test the effect of two behavioral interventions targeted to junior physicians-specifically, requiring them to specify the diagnosis in the prescription note and providing feedback-on their antibiotics prescription rate; examine the intervention's effects across gender and caste; and draw lessons for scaling up the intervention.

Read the detailed description

Antimicrobial resistance (AMR) is one of the top ten threats to global health. Limited existing evidence from Nepal, the site for the proposed study, suggests that physicians "err on the side of caution" by prescribing antibiotics even for viral conditions, which contributes to AMR. Interventions that are low-cost, do not add substantially to the physician workload, are consistent with good physician practices and WHO guidelines, and serve as a reminder on the risks of overprescribing antibiotics are critically needed. The overall goal of the proposed project is to test the effect of a behavioral intervention targeted to junior physicians-specifically, requiring them to specify the diagnosis in the prescription note and providing feedback-on their antibiotics prescription rate; examine the intervention's effects across gender and caste; and draw lessons for scaling up the intervention.

The specific objectives are the following:

Objective 1. Assess the effect of a behavioral intervention targeted to junior physicians on antibiotics prescription rate, including by caste and gender of the patient. A stepped-wedge randomized control trial (RCT) will be conducted among 60 junior physicians in five hospitals (1 government, 2 private teaching, and 2 community) in Nepal. The intervention will be rolled out sequentially across the hospitals and data will be collected from patients (n=3,600) both before and after the intervention. The intervention will consist of three components: (a) a Refresher Training on AMR, (b) a Diagnosis Mandate, and (c) an Individualized Feedback.

Objective 2. Identify barriers to scaling up the intervention beyond the study's site and strategies for their mitigation. After preliminary analysis of the quantitative data, key informant interviews with national- and provincial- level health policy makers (n=5), and in-depth interviews with physicians (n=5) and hospital managers (n=5) will be conducted.

Objective 3. Assess the extent to which physicians prescribe antibiotics correctly. From a subset of patients (n=120, i.e., 2 per physician), more detailed medical information will be collected and analyzed from their outpatient booklet.

This registration is for objective 1. Therefore, only details pertaining to that objective will be provided here.

02

Conditions studied

  • Antimicrobial Resistance
03

In context

Lead sponsor

Penn State University is the lead sponsor of 263 studies on the registry; 51 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 10 (77%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

For physicians:

Inclusion criteria:

  • age 18+
  • working at an outpatient clinic in one of the participating hospitals.

Exclusion criteria:

  • \<18 years of age
  • working at more than one of the participating hospitals

For patients:

Inclusion criteria:

  • age 18+
  • sought care at one of the outpatient clinics in the participating hospitals.

Exclusion criteria:

  • \<18 years of age
  • one of the vulnerable populations (pregnant women, cognitively impaired adults)
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Care provider)
Enrollment
62 participants (actual)

Study arms

  • No intervention
    Control

    During this phase, physicians do not receive any intervention.

  • Experimental
    Diagnosis Mandate

    In this phase, physicians receive a refresher training on AMR and a letter requiring the physicians to specify the diagnosis in their prescription note.

    Behavioral: Diagnosis Mandate

  • Experimental
    Feedback

    In this phase, physicians receive a customized feedback letter on their prescription behavior, including antibiotics prescription rate.

    Behavioral: Individualized Feedback

Interventions

  • BehavioralDiagnosis Mandate

    The intervention consists of: a) a Refresher Training on AMR, and (b) a Diagnosis Mandate.

  • BehavioralIndividualized Feedback

    Physicians receive a customized feedback on their prescription behavior, including antibiotics prescription rate.

06

What researchers measure

Primary outcomes

  1. Antibiotics prescription rate

    The number of patient visits in which antibiotics are prescribed by the total number of visits

    Time frame: 1-3 months before the intervention and 3-5 months after the intervention, depending on the timing of the intervention which varies by hospital.

Secondary outcomes

  1. Differences in prescription rates by patient's gender

    The number of patient visits in which antibiotics are prescribed by the total number of visits, by male and female

    Time frame: 1-3 months before the intervention and 3-5 months after the intervention, depending on the timing of the intervention which varies by hospital.

  2. Differences in prescription rates by patient's ethnicity (advantaged versus disadvantaged)

    The number of patient visits in which antibiotics are prescribed by the total number of visits, by advantaged and disadvantaged status

    Time frame: 1-3 months before the intervention and 3-5 months after the intervention, depending on the timing of the intervention which varies by hospital.

07

Study locations

2 sites
  • Pennsylvania State University
    University Park, Pennsylvania 16801, United States
  • Institute for Social and Environmental Research - Nepal
    Bharatpur, Bagmati 44200, Nepal
08

References and documents

Individual participant data

Plan to share: No — There are potential risks about confidentiality, as the number of physicians is small.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06436690
Lead sponsor
Penn State University
Responsible party
Yubraj Acharya, Ph.D. (Associate Professor, Penn State University) — Principal investigator
First posted
May 31, 2024
Start date
Apr 15, 2025
Primary completion
Nov 28, 2025
Completion
Dec 30, 2026 (estimated)
Last update
Jul 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion